Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
Revenue Downgrade: Here's What Analysts Forecast For Sangamo Therapeutics, Inc. (NASDAQ:SGMO)
Today is shaping up negative for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly drac
Sangamo Therapeutics Shares Drop 15% After $24M Offering Prices
By Chris Wack Sangamo Therapeutics shares were down 14% to 83 cents after the company entered a securities purchase agreement with institutional investors for the purchase and sale of 24.8 million sh
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differentiated adeno-associated virus (AAV)-based TRACER capsids with the pote
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics with a Buy and raises the price target from $3 to $5.
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says
Sangamo Therapeutics' (SGMO) emphasis remains on progressing neurology programs toward clinical development, Wedbush said in a report Thursday. The company reported Q4 results on Wednesday and provide
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
RBC Capital analyst Luca Issi reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Sector Perform and maintains $2 price target.
Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 50% Share Price Rise
Despite an already strong run, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares have been powering on, with a gain of 50% in the last thirty days. But the last month did very little to improve the 6
HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Patrick Trucchio maintains Sangamo Therapeutics with a Buy and maintains $3 price target.
Sangamo Therapeutics Expects Total Operating Expenses In The Range Of ~$145M-$165M In 2024
Financial Guidance for 2024On a GAAP basis, we expect total operating expenses in the range of approximately $145 million to $165 million in 2024, which includes non-cash stock-based compensation expe
Sangamo Therapeutics Q4 EPS $(0.34) Misses $(0.26) Estimate, Sales $2.04M Miss $8.10M Estimate
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 6.25 percent decrease over losses o
Sangamo Therapeutics 4Q Rev $2.04M >SGMO
Sangamo Therapeutics 4Q Rev $2.04M >SGMO
Press Release: Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results -- Data from novel proprietary neurotropic adeno-associated virus (AAV) deliv
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Novel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following intravenous
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expec
Press Release: Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast RICHMOND, Calif.--(BUSINESS WIRE)--March 12, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic
No Data